Literature DB >> 30408649

Novel 4-(3-phenylpropionamido), 4-(2-phenoxyacetamido) and 4-(cinnamamido) substituted benzamides bearing the pyrazole or indazole nucleus: synthesis, biological evaluation and mechanism of action.

Demetrio Raffa1, Antonella D'Anneo2, Fabiana Plescia3, Giuseppe Daidone4, Marianna Lauricella5, Benedetta Maggio4.   

Abstract

Based on some common structural features of known compounds interfering with p53 pathways and our previously synthesized benzamides, we synthesized new ethyl 5-(4-substituted benzamido)-1-phenyl-1H-pyrazole-4-carboxylates 26a-c, ethyl 5-(4-substituted benzamido)-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylates 27a-c and N-(1H-indazol-6-yl)-4-substituted benzamides 31a,b bearing in the 4 position of the benzamido moiety the 2-phenylpropanamido or 2-phenoxyacetamido or cinnamamido groups. A preliminary test to evaluate the antiproliferative activity against human lung carcinoma H292 cells highlighted how compound 26c showed the best activity. This last was therefore selected for further studies with the aim to find the mechanism of action. Compound 26c induces intrinsic apoptotic pathway by activating p53 and is also able to activate TRAIL-inducing death pathway by promoting increase of DR4 and DR5 death receptors, downregulation of c-FLIPL and caspase-8 activation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2-(2-phenoxyacetamido)benzamides; 2-(3-phenylpropanamido)benzamides; 2-cinnamamidobenzamides; Apoptosis; P53; TRAIL-receptors

Mesh:

Substances:

Year:  2018        PMID: 30408649     DOI: 10.1016/j.bioorg.2018.10.055

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  1 in total

1.  Pyrazole Derivatives Induce Apoptosis via ROS Generation in the Triple Negative Breast Cancer Cells, MDA-MB-468.

Authors:  Maryam Ashourpour; Fatemeh Mostafavi Hosseini; Mohsen Amini; Ebrahim Saeedian Moghadam; Faranak Kazerouni; Seyed Yousef Arman; Zahra Shahsavari
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.